Immunotherapy may help patients with the kind of cancer that killed John McCain
Glioblastoma is one of the deadliest of cancers, killing almost all its victims, who have included Ted Kennedy, John McCain and Beau Biden. But a new, early phase study offers a sliver of hope that drugs that rally the immune system may help some patients live longer.
Conditions: Colorectal Liver Metastases; Colorectal Cancer; Liver Metastases; Immunotherapy Intervention: Procedure: Hepatectomy Sponsor: Humanitas Clinical and Research Center Completed
PLYMOUTH MEETING, Pa., March 25, 2019 -- (Healthcare Sales &Marketing Network) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Dr. Ann C. Miller to its Board of Directors. Dr. Miller had an outstanding marketing career la... Biopharmaceuticals, Oncology, Personnel Inovio Pharmaceuticals, immunotherapy, cancer vaccine
Hookipa Pharma, a Phase 2 biotech developing T cell immunotherapies for various cancers, filed with the SEC to raise up to $86 million in an initial public offering.
Date: Wednesday, 04 17, 2019; Speaker: Thomas Gajewski, MD, PhD, Professor, Departments of Pathology, , Medicine, and the Ben May Institute and Program Leader, Immunology and Cancer , Program, University Chicago Comprehensive Cancer Center; Building: Building 10 (Clinical Center); Lipsett Amphitheater; CME Credit; Videocast Event
Among the updates are expanded treatment options, including a recently approved immunotherapy regimen for locally advanced or metastatic disease.
(Stand Up To Cancer) Stand Up To Cancer awards the inaugural SU2C Peggy Prescott Early Career Scientist Award in Colorectal Cancer Research, funded by Dallas Cowboys QB Dak Prescott in memory of his mother. Karin Pelka, Ph.D. (the Broad Institute of MIT and Harvard) receives $50,000 over two years to conduct research focusing on bypassing immunotherapy resistance in CRC treatment, in collaboration with members of the SU2C Colorectal Dream Team at Massachusetts General Hospital and the Broad Institute.
(University of Texas M. D. Anderson Cancer Center) White blood cells known as B cells have been shown to be effective for predicting which cancer patients will respond to immune checkpoint blockade (ICB) therapy, according to a study at The University of Texas MD Anderson Cancer Center. Study results will be presented April 2 at the AACR Annual Meeting 2019 in Atlanta.
Researchers say doctors will need clear guidance to ensure they can support patients Related items fromOnMedica Cancer strategies failed to improve one-year survival Obesity as cause of cancer set to overtake smoking Is the NHS ready for ‘Cutting edge’ CAR T cell immunotherapy? AI developments in medical imaging will 'save lives and time' NICE calls on GPs to diagnose cancer sooner
ConclusionsThis report suggests that systemic immunotherapy with or without topical interferon is effective in treatment of malignant melanoma of the conjunctiva. Therefore, it can be considered for patients with advanced local conjunctival melanoma, those who refuse orbital exenteration surgery and those with systemic metastasis.
Authors: Smith WM, Purvis IJ, Bomstad CN, Labak CM, Velpula KK, Tsung AJ, Regan JN, Venkataraman S, Vibhakar R, Asuthkar S Abstract Immune checkpoints are known to contribute to tumor progression by enhancing cancer's ability to evade the immune system and metastasize. Immunotherapies, including monoclonal antibodies, have been developed to target specific immunosuppressive molecules on the membranes of cancer cells and have proven revolutionary in the field of oncology. Recently, small molecule inhibitors (SMIs) have gained increased attention in cancer research with potential applications in immunotherapy. SMIs h...